PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 10-Q

ITEM 5. OTHER INFORMATION Securities Trading Plans of Directors and Executive Officers During our last fiscal quarter ended June 30, 2026, Jim R. Gibson , our Chief Financial Officer , adopted a Rule 10b5-1 trading arrangement on May 22, 2026 . The trading arrangement is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended, has a planned duration from August 21, 2026 through March 15, 2027 , and provides for the potential sale of up to 661,685 shares of the Company's common stock. Other than as disclosed above, none of our directors or officers, as defined in Rule 16a-1(f), adopted and/or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408. Q2 Fiscal 2026 Form 10-Q 88 Table of Contents ITEM 6. EXHIBITS Incorporated by reference herein Exhibit No. Description Form Exhibit No. Filing Date 3.1 Amended and Restated Certificate of Incorporation of Pacific Biosciences of California, Inc. 10-K 3.1 March 23, 2011 3.2 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Pacific Biosciences of California, Inc. to declassify the Board 8-K 3.1 June 20, 2024 3.3 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Pacific Biosciences of California, Inc. to limit the liability of officers 8-K 3.2 June 20, 2024 3.4 Third Amended and Restated Bylaws of Pacific Biosciences of California, Inc. 8-K 3.1 November 7, 2022 1 0.1+ Pacific Biosciences of California, Inc. 2020 Equity Incentive Plan, as amended 8-K 10.1 June 4, 2026 31 .1 Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Filed herewith 31 .2 Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Filed herewith 32.1 * Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Furnished herewith 32.2 * Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Furnished herewith 101.INS XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) Filed herewith 101.SCH Inline XBRL Taxonomy Extension Schema Document Filed herewith 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document Filed herewith 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document Filed herewith 101.LAB Inline XBRL Taxonomy Extension Labels Linkbase Document Filed herewith 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document Filed herewith 104 Cover Page Interactive File (formatted as inline XBRL and contained in Exhibit 101) Filed herewith ______________________________________________________________________________ + Indicates management contract or compensatory plan. * The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Pacific Biosciences of California, Inc. under the Securities Act or the Exchange Act, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing. Q2 Fiscal 2026 Form 10-Q 89 Table of Contents Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Pacific Biosciences of California, Inc. Date: August 6, 2026 By: /s/ Mark Van Oene Mark Van Oene President and Chief Executive Officer (Principal Executive Officer) Date: August 6, 2026 By: /s/ Jim R. Gibson Jim R. Gibson Chief Financial Officer (Principal Financial and Accounting Officer) Q2 Fiscal 2026 Form 10-Q 90